{"transactions":[{"id":671071,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial & Infra. Ofcr."}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:53:24.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":41.21,"value":2060500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":43.79,"expiration_date":"2036-02-23","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001628280-26-059883","document":"wk-form4_1788296002.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059883/wk-form4_1788296002.xml","form_type":"4"}},{"id":671070,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial & Infra. Ofcr."}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:53:24.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"price":51.25,"value":4100000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":33.75,"expiration_date":"2035-03-09","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001628280-26-059883","document":"wk-form4_1788296002.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059883/wk-form4_1788296002.xml","form_type":"4"}},{"id":671069,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial & Infra. Ofcr."}}],"security":"Common Stock","published_at":"2026-09-01T20:53:24.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":71471,"price":85,"value":6075035.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a \"Company RSU\"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059883","document":"wk-form4_1788296002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059883/wk-form4_1788296002.xml","form_type":"4"}},{"id":671068,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial & Infra. Ofcr."}}],"security":"Common Stock","published_at":"2026-09-01T20:53:24.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7956,"price":85,"value":676260.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":71471,"source":{"system":"sec-edgar","filing":"0001628280-26-059883","document":"wk-form4_1788296002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059883/wk-form4_1788296002.xml","form_type":"4"}},{"id":677366,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial & Infra. Ofcr."}}],"security":"Common Stock","published_at":"2026-08-24T20:52:32.000Z","date":"2026-08-20","kind":"grant","planned":false,"acquired":true,"shares":471,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on September 1, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":79427,"source":{"system":"sec-edgar","filing":"0001628280-26-058664","document":"wk-form4_1787604750.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026058664/wk-form4_1787604750.xml","form_type":"4"}},{"id":861575,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T22:43:52.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":6713,"price":39.67,"value":266304.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 10, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $39.67 per share. The range of sales prices on the transaction date was $39.67 to $39.74 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":78121,"source":{"system":"sec-edgar","filing":"0001628280-26-014772","document":"wk-form4_1772664230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026014772/wk-form4_1772664230.xml","form_type":"4"}},{"id":881977,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-25T21:36:22.000Z","date":"2026-02-23","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026."}],"balance_after":50000,"derivative":{"exercise_price":43.79,"expiration_date":"2036-02-23","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001628280-26-011728","document":"wk-form4_1772055379.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026011728/wk-form4_1772055379.xml","form_type":"4"}},{"id":881976,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-25T21:36:22.000Z","date":"2026-02-23","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 834 shares acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":84834,"source":{"system":"sec-edgar","filing":"0001628280-26-011728","document":"wk-form4_1772055379.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026011728/wk-form4_1772055379.xml","form_type":"4"}},{"id":1212157,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-11T20:30:06.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2026, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":33.75,"expiration_date":"2035-03-09","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000950170-25-037200","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025037200/ownership.xml","form_type":"4"}},{"id":1212156,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-11T20:30:06.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2026."}],"balance_after":52000,"source":{"system":"sec-edgar","filing":"0000950170-25-037200","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025037200/ownership.xml","form_type":"4"}},{"id":1280289,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2025-02-06T15:59:07.000Z","date":"2025-02-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20883,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each PSU award then outstanding and not vested was canceled and converted into the right to receive a lump sum cash payment, without interest thereon and subject to applicable withholding taxes, equal to the product of (i) the Per Share Price multiplied by (ii) the number of Shares subject to such PSU award (with the performance metrics deemed achieved as set forth in the Merger Agreement)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-015362","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015362/ownership.xml","form_type":"4"}},{"id":1280288,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2025-02-06T15:59:07.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":20883,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents a deemed acquisition of the Shares underlying a portion of the performance-based restricted stock units (\"PSUs\") granted on January 31, 2023, pursuant to the terms of the Merger Agreement."}],"balance_after":20883,"source":{"system":"sec-edgar","filing":"0000950170-25-015362","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015362/ownership.xml","form_type":"4"}},{"id":1280287,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2025-02-06T15:59:07.000Z","date":"2025-02-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":103555,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each Issuer restricted stock unit (\"RSU\") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-015362","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015362/ownership.xml","form_type":"4"}},{"id":1280286,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2025-02-06T15:59:07.000Z","date":"2025-02-04","kind":"other","planned":false,"acquired":false,"shares":97999,"price":3.65,"value":357696.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the \"Merger Agreement\"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation (\"Parent\"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub,\" and together with Parent, the \"Buyer Parties\"), pursuant to which Merger Sub completed a cash tender offer (the \"Offer\") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the \"Shares\"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the \"Per Share Price\"). These Issuer Shares were tendered for purchase pursuant to the Offer."}],"balance_after":103555,"source":{"system":"sec-edgar","filing":"0000950170-25-015362","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015362/ownership.xml","form_type":"4"}},{"id":1281776,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2025-02-05T19:53:31.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":6888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the vesting of performance-based restricted stock units (PSUs) granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. On February 3, 2025, the Issuer's Compensation Committee certified a portion of the PSUs eligible to vest based on (i) the achievement of a revenue goal, measured beginning January 1, 2024 through December 31, 2024, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date."}],"balance_after":201554,"source":{"system":"sec-edgar","filing":"0000950170-25-014824","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025014824/ownership.xml","form_type":"4"}},{"id":1314559,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2025-01-03T16:34:15.000Z","date":"2024-12-31","kind":"grant","planned":false,"acquired":true,"shares":1000,"price":2.1845,"value":2184.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2024 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":194666,"source":{"system":"sec-edgar","filing":"0001479290-25-000005","document":"wk-form4_1735940046.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929025000005/wk-form4_1735940046.xml","form_type":"4"}},{"id":1462915,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2024-07-02T17:47:03.000Z","date":"2024-06-30","kind":"grant","planned":false,"acquired":true,"shares":1000,"price":2.1845,"value":2184.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2024 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":193666,"source":{"system":"sec-edgar","filing":"0001479290-24-000103","document":"wk-form4_1719956817.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000103/wk-form4_1719956817.xml","form_type":"4"}},{"id":1568509,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2024-03-19T18:44:03.000Z","date":"2024-03-18","kind":"sale","planned":false,"acquired":false,"shares":9361,"price":5.0426,"value":47203.7786,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units (\"PSUs\") granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals.  This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Table 1, Column 4 is a weighted average price.  These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":192666,"source":{"system":"sec-edgar","filing":"0001479290-24-000066","document":"wk-form4_1710888231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000066/wk-form4_1710888231.xml","form_type":"4"}},{"id":1568508,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2024-03-19T18:44:03.000Z","date":"2024-03-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":3822,"price":5.305,"value":20275.71,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the \"RSA\") for 7,540 shares. The RSA vested in three equal annual installments from March 15, 2021."}],"balance_after":202027,"source":{"system":"sec-edgar","filing":"0001479290-24-000066","document":"wk-form4_1710888231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000066/wk-form4_1710888231.xml","form_type":"4"}},{"id":1602920,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2024-03-04T16:44:22.000Z","date":"2024-02-29","kind":"grant","planned":false,"acquired":true,"shares":17447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the vesting of performance-based restricted stock units (PSUs) granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals.  On February 29, 2024, the Issuer's Compensation Committee certified a portion of the PSUs eligible to vest  based on (i) the achievement of a revenue goal, measured beginning January 1, 2023 through December 31, 2023, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date of March 15, 2024."}],"balance_after":205849,"source":{"system":"sec-edgar","filing":"0001479290-24-000051","document":"wk-form4_1709588228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000051/wk-form4_1709588228.xml","form_type":"4"}},{"id":1661577,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Performance Stock Units","published_at":"2024-02-02T16:46:53.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":145001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is\ncontingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with  the Company through the vesting dates."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is\ncontingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with  the Company through the vesting dates."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of  securities reported represents the maximum shares that can be earned."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is\ncontingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with  the Company through the vesting dates."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of  securities reported represents the maximum shares that can be earned."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of  securities reported represents the maximum shares that can be earned."}],"balance_after":145001,"derivative":{"exercise_date":"2025-02-15","expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":145001},"source":{"system":"sec-edgar","filing":"0001479290-24-000015","document":"wk-form4_1706910393.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000015/wk-form4_1706910393.xml","form_type":"4"}},{"id":1661576,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2024-02-02T16:46:53.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":96667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the Restricted Stock Unit shall vest in three (3) equal annual installments beginning from February 15, 2025, subject to the reporting person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date."}],"balance_after":188402,"source":{"system":"sec-edgar","filing":"0001479290-24-000015","document":"wk-form4_1706910393.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000015/wk-form4_1706910393.xml","form_type":"4"}},{"id":1692230,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2024-01-03T16:48:58.000Z","date":"2023-12-31","kind":"grant","planned":false,"acquired":true,"shares":434,"price":7.47,"value":3241.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2023 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":91735,"source":{"system":"sec-edgar","filing":"0001479290-24-000005","document":"wk-form4_1704318504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000005/wk-form4_1704318504.xml","form_type":"4"}},{"id":1807301,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-08-15T16:16:00.000Z","date":"2023-08-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":11215,"price":18.91,"value":212075.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by and surrendered to the Issuer on August 11, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the PSA."}],"balance_after":91301,"source":{"system":"sec-edgar","filing":"0001479290-23-000099","document":"wf-form4_169213053920271.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000099/wf-form4_169213053920271.xml","form_type":"4"}},{"id":1807300,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-08-15T16:16:00.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":22620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the vesting of a performance-based restricted stock award (PSA) granted on February 2, 2021. On August 11, 2023, the Issuer's Compensation Committee certified 100% of the PSAs eligible to vest based on (i) the achievement of a cumulative revenue goal, calculated in accordance with GAAP, adjusted to exclude revenue recognized from collaboration agreements and classified as collaboration revenue, measured beginning on January 1, 2021, provided the goal is achieved on or before the three-year anniversary of the U.S. Food and Drug Administration's approval of the Issuer's biologics license application for DAXXIFY(R) for the improvement of glabellar lines, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date."}],"balance_after":102516,"source":{"system":"sec-edgar","filing":"0001479290-23-000099","document":"wf-form4_169213053920271.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000099/wf-form4_169213053920271.xml","form_type":"4"}},{"id":1836060,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-07-05T21:11:46.000Z","date":"2023-07-03","kind":"sale","planned":true,"acquired":false,"shares":1701,"price":25.04,"value":42593.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke."}],"balance_after":79896,"source":{"system":"sec-edgar","filing":"0001479290-23-000083","document":"wf-form4_168860588867593.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000083/wf-form4_168860588867593.xml","form_type":"4"}},{"id":1836059,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-07-05T21:11:46.000Z","date":"2023-06-30","kind":"grant","planned":true,"acquired":true,"shares":769,"price":15.606,"value":12001.014,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2023 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":81597,"source":{"system":"sec-edgar","filing":"0001479290-23-000083","document":"wf-form4_168860588867593.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000083/wf-form4_168860588867593.xml","form_type":"4"}},{"id":1866968,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-06-05T18:06:03.000Z","date":"2023-06-02","kind":"sale","planned":true,"acquired":false,"shares":500,"price":31,"value":15500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke."}],"balance_after":80828,"source":{"system":"sec-edgar","filing":"0001479290-23-000077","document":"wf-form4_168600274920722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000077/wf-form4_168600274920722.xml","form_type":"4"}},{"id":1866967,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-06-05T18:06:03.000Z","date":"2023-06-01","kind":"sale","planned":true,"acquired":false,"shares":2701,"price":30.57,"value":82569.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke."}],"balance_after":81328,"source":{"system":"sec-edgar","filing":"0001479290-23-000077","document":"wf-form4_168600274920722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000077/wf-form4_168600274920722.xml","form_type":"4"}},{"id":1891454,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-05-16T20:29:33.000Z","date":"2023-05-15","kind":"sale","planned":false,"acquired":false,"shares":21401,"price":34.5469,"value":739338.2069,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.01 to $34.55. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":84029,"source":{"system":"sec-edgar","filing":"0001479290-23-000075","document":"wf-form4_168428336033050.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000075/wf-form4_168428336033050.xml","form_type":"4"}},{"id":1891453,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-05-16T20:29:33.000Z","date":"2022-02-02","kind":"grant","planned":false,"acquired":true,"shares":42349,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents settlement of a performance-based restricted stock unit (\"PSU\") granted on February 2, 2022. On May 12, 2023, the Issuer's Compensation Committee certified 100% of the PSUs eligible to vest based on pre-established criteria related to the price of the Issuer's common stock."}],"balance_after":105430,"source":{"system":"sec-edgar","filing":"0001479290-23-000075","document":"wf-form4_168428336033050.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000075/wf-form4_168428336033050.xml","form_type":"4"}},{"id":1908216,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-05-02T16:01:32.000Z","date":"2023-05-01","kind":"sale","planned":true,"acquired":false,"shares":3201,"price":31.7,"value":101471.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke."}],"balance_after":63081,"source":{"system":"sec-edgar","filing":"0001479290-23-000056","document":"wf-form4_168305767740098.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000056/wf-form4_168305767740098.xml","form_type":"4"}},{"id":1927964,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-04-04T16:24:26.000Z","date":"2023-04-03","kind":"sale","planned":true,"acquired":false,"shares":3201,"price":32.15,"value":102912.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke."}],"balance_after":66282,"source":{"system":"sec-edgar","filing":"0001479290-23-000053","document":"wf-form4_168063984837857.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000053/wf-form4_168063984837857.xml","form_type":"4"}},{"id":1946890,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-03-17T15:21:53.000Z","date":"2023-03-15","kind":"tax_withholding","acquired":false,"shares":3739,"price":30.65,"value":114600.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the\"RSA\") for 7,540 shares. The RSA vests in three equal annual installments from March 15, 2021."}],"balance_after":69483,"source":{"system":"sec-edgar","filing":"0001479290-23-000041","document":"wf-form4_167908089885096.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000041/wf-form4_167908089885096.xml","form_type":"4"}},{"id":1960918,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-03-09T21:46:08.000Z","date":"2023-03-09","kind":"sale","acquired":false,"shares":18517,"price":31.5863,"value":584883.5171,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":73222,"source":{"system":"sec-edgar","filing":"0001479290-23-000036","document":"wf-form4_167841635608608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000036/wf-form4_167841635608608.xml","form_type":"4"}},{"id":1960917,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-03-09T21:46:08.000Z","date":"2022-09-22","kind":"grant","acquired":true,"shares":42349,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents settlement of a performance-based restricted stock unit (\"PSU\") granted on February 2, 2022. On September 22, 2022, the Company's Compensation Committee certified 100% of the PSUs eligible to vest based on i) the achievement of the U.S. Food and Drug Administration's (\"FDA\") approval of the Issuer's biologics license application (BLA) for DAXXIFY(R) for the improvement of glabellar lines (\"FDA Approval\") and ii) subject to the Reporting Person remaining in continuous service through the six-month anniversary following the date of the FDA Approval which six-month anniversary was March 7, 2023."}],"balance_after":91739,"source":{"system":"sec-edgar","filing":"0001479290-23-000036","document":"wf-form4_167841635608608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000036/wf-form4_167841635608608.xml","form_type":"4"}},{"id":1979355,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-03-02T21:25:57.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":3201,"price":33.5,"value":107233.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke."}],"balance_after":49390,"source":{"system":"sec-edgar","filing":"0001479290-23-000031","document":"wf-form4_167781034001694.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000031/wf-form4_167781034001694.xml","form_type":"4"}},{"id":2010944,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-02-16T20:28:40.000Z","date":"2023-02-15","kind":"tax_withholding","acquired":false,"shares":2085,"price":33.21,"value":69242.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award (the \"RSA\") for 5,500 shares. The RSA vested in three equal annual installments from February 15, 2020."}],"balance_after":52591,"source":{"system":"sec-edgar","filing":"0001479290-23-000018","document":"wf-form4_167659730390739.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000018/wf-form4_167659730390739.xml","form_type":"4"}},{"id":2035924,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-02-02T21:38:15.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":50435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from January 31, 2023, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date."}],"balance_after":50435,"derivative":{"exercise_price":34.68,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":50435},"source":{"system":"sec-edgar","filing":"0001479290-23-000015","document":"wf-form4_167539188027302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000015/wf-form4_167539188027302.xml","form_type":"4"}},{"id":2035923,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-02-02T21:38:15.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":3201,"price":34.6,"value":110754.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,953 shares purchased pursuant to the Issuer's 2014 Employee Stock Purchase Plan."}],"balance_after":54676,"source":{"system":"sec-edgar","filing":"0001479290-23-000015","document":"wf-form4_167539188027302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000015/wf-form4_167539188027302.xml","form_type":"4"}},{"id":2048649,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-01-23T17:35:36.000Z","date":"2023-01-20","kind":"sale","acquired":false,"shares":1000,"price":31,"value":31000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,716 shares purchased pursuant to the Issuer's 2014 Employee Stock Purchase Plan."}],"balance_after":57877,"source":{"system":"sec-edgar","filing":"0001479290-23-000012","document":"wf-form4_167451332217569.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000012/wf-form4_167451332217569.xml","form_type":"4"}},{"id":2057486,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-01-10T20:06:54.000Z","date":"2023-01-09","kind":"sale","acquired":false,"shares":1000,"price":30,"value":30000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke."}],"balance_after":58877,"source":{"system":"sec-edgar","filing":"0001479290-23-000007","document":"wf-form4_167339919617880.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000007/wf-form4_167339919617880.xml","form_type":"4"}},{"id":2057485,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-01-10T20:06:54.000Z","date":"2023-01-09","kind":"sale","acquired":false,"shares":1000,"price":28,"value":28000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke."}],"balance_after":59877,"source":{"system":"sec-edgar","filing":"0001479290-23-000007","document":"wf-form4_167339919617880.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000007/wf-form4_167339919617880.xml","form_type":"4"}},{"id":2057484,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-01-10T20:06:54.000Z","date":"2023-01-09","kind":"sale","acquired":false,"shares":1701,"price":25,"value":42525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke."}],"balance_after":60877,"source":{"system":"sec-edgar","filing":"0001479290-23-000007","document":"wf-form4_167339919617880.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000007/wf-form4_167339919617880.xml","form_type":"4"}},{"id":2072532,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-01-03T16:29:03.000Z","date":"2022-12-31","kind":"grant","acquired":true,"shares":645,"price":12.1805,"value":7856.4225,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2022 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":62578,"source":{"system":"sec-edgar","filing":"0001479290-23-000003","document":"wf-form4_167278132182264.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000003/wf-form4_167278132182264.xml","form_type":"4"}},{"id":2083622,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2022-12-16T16:12:11.000Z","date":"2022-12-15","kind":"tax_withholding","acquired":false,"shares":1557,"price":21.5,"value":33475.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award (\"RSA\") for 4,500 shares. The RSA vests in four equal annual installments from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date."}],"balance_after":61933,"source":{"system":"sec-edgar","filing":"0001479290-22-000106","document":"wf-form4_167122509909406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000106/wf-form4_167122509909406.xml","form_type":"4"}},{"id":2214608,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2022-07-05T18:15:00.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":965,"price":11.747,"value":11335.855,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2022 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":63490,"source":{"system":"sec-edgar","filing":"0001479290-22-000072","document":"wf-form4_165705928528709.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000072/wf-form4_165705928528709.xml","form_type":"4"}},{"id":2327315,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-17T17:48:05.000Z","date":"2022-03-15","kind":"tax_withholding","acquired":false,"shares":2607,"price":15.79,"value":41164.53,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the \"RSA\") for 22,620 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date."}],"balance_after":62525,"source":{"system":"sec-edgar","filing":"0001209191-22-019713","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919122019713/doc4.xml","form_type":"4"}},{"id":2388377,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2022-02-17T20:49:18.000Z","date":"2022-02-15","kind":"tax_withholding","acquired":false,"shares":683,"price":13.35,"value":9118.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of an RSA for 5,000 shares.  The RSA vests in three equal annual installments from February 15, 2019, subject to Mr. Schilke's Continuous Service (as defined in the Plan) on each vesting date."}],"balance_after":65132,"source":{"system":"sec-edgar","filing":"0001479290-22-000021","document":"wf-form4_164514894332397.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000021/wf-form4_164514894332397.xml","form_type":"4"}},{"id":2388376,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2022-02-17T20:49:18.000Z","date":"2022-02-15","kind":"tax_withholding","acquired":false,"shares":2241,"price":13.35,"value":29917.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award (\"RSA\") for 16,500 shares.  The RSA vests in three equal annual installments from February 15, 2020, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the \"Plan.\")) on each vesting date."}],"balance_after":65815,"source":{"system":"sec-edgar","filing":"0001479290-22-000021","document":"wf-form4_164514894332397.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000021/wf-form4_164514894332397.xml","form_type":"4"}},{"id":2411650,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-02-04T20:31:58.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":68093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 2, 2022, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date."}],"balance_after":68093,"derivative":{"exercise_price":13.08,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":68093},"source":{"system":"sec-edgar","filing":"0001479290-22-000014","document":"wf-form4_164402470162531.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000014/wf-form4_164402470162531.xml","form_type":"4"}},{"id":2448957,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2022-01-04T20:58:29.000Z","date":"2021-12-31","kind":"other","acquired":true,"shares":404,"price":13.872,"value":5604.288,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan (the \"Plan\") on December 31,2021 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":68056,"source":{"system":"sec-edgar","filing":"0001479290-22-000002","document":"wf-form4_164134789553273.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000002/wf-form4_164134789553273.xml","form_type":"4"}},{"id":2466009,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-12-17T17:31:04.000Z","date":"2021-12-15","kind":"tax_withholding","acquired":false,"shares":1556,"price":15.92,"value":24771.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2021, to satisfy tax withholding obligations that arose in connection with the vesting of 4,500 shares of a Restricted Stock award (\"RSA\") for 18,000 shares.  The RSA vests in four equal annual installments from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date."}],"balance_after":67652,"source":{"system":"sec-edgar","filing":"0001479290-21-000177","document":"wf-form4_163978024325249.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000177/wf-form4_163978024325249.xml","form_type":"4"}},{"id":2644536,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-07-02T19:53:56.000Z","date":"2021-06-30","kind":"other","acquired":true,"shares":446,"price":24.089,"value":10743.694,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2021 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":69208,"source":{"system":"sec-edgar","filing":"0001479290-21-000132","document":"wf-form4_162527001681770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000132/wf-form4_162527001681770.xml","form_type":"4"}},{"id":2846123,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-02-19T20:15:24.000Z","date":"2021-02-15","kind":"tax_withholding","acquired":false,"shares":1973,"price":28.97,"value":57157.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2021, to satisfy tax withholding obligations that arose in connection with the vesting of the Restricted Stock award (\"RSA\") for 16,500 shares.  The RSA vests in three equal annual installments from February 15, 2020, subject to Mr. Schilke's Continuous Service (as defined in the Plan) on each vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The fair market value was determined on February 12, 2021 pursuant to the Plan."}],"balance_after":68762,"source":{"system":"sec-edgar","filing":"0001479290-21-000047","document":"wf-form4_161378368820459.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000047/wf-form4_161378368820459.xml","form_type":"4"}},{"id":2846122,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-02-19T20:15:24.000Z","date":"2021-02-15","kind":"tax_withholding","acquired":false,"shares":684,"price":28.97,"value":19815.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2021, to satisfy tax withholding obligations that arose in connection with the vesting of the Restricted Stock award (\"RSA\") for 5,000 shares.  The RSA vests in three equal annual installments from February 15, 2019, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the \"Plan.\")) on each vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The fair market value was determined on February 12, 2021 pursuant to the Plan."}],"balance_after":70735,"source":{"system":"sec-edgar","filing":"0001479290-21-000047","document":"wf-form4_161378368820459.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000047/wf-form4_161378368820459.xml","form_type":"4"}},{"id":2879149,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-02-04T21:15:57.000Z","date":"2021-02-02","kind":"grant","acquired":true,"shares":40925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 2, 2021, subject to Mr. Schilke's Continuous Service (as defined in the Plan) on each vesting date."}],"balance_after":40925,"derivative":{"exercise_price":28.01,"expiration_date":"2031-02-01","underlying":"Common Stock","underlying_shares":40925},"source":{"system":"sec-edgar","filing":"0001479290-21-000035","document":"wf-form4_161249134328472.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000035/wf-form4_161249134328472.xml","form_type":"4"}},{"id":2879148,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-02-04T21:15:57.000Z","date":"2021-02-02","kind":"grant","acquired":true,"shares":22620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from March 15, 2021, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date."}],"balance_after":71419,"source":{"system":"sec-edgar","filing":"0001479290-21-000035","document":"wf-form4_161249134328472.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000035/wf-form4_161249134328472.xml","form_type":"4"}},{"id":2925563,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-01-04T20:02:57.000Z","date":"2020-12-31","kind":"other","acquired":true,"shares":493,"price":21.3605,"value":10530.7265,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2020 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":48799,"source":{"system":"sec-edgar","filing":"0001479290-21-000009","document":"wf-form4_160980856502255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000009/wf-form4_160980856502255.xml","form_type":"4"}},{"id":2934620,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2020-12-22T20:39:43.000Z","date":"2020-12-15","kind":"tax_withholding","acquired":false,"shares":1556,"price":26.75,"value":41623.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award (\"RSA\") for 4,500 shares.  The RSA vests in four equal annual installments from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date."}],"balance_after":48306,"source":{"system":"sec-edgar","filing":"0001479290-20-000118","document":"wf-form4_160868756377806.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929020000118/wf-form4_160868756377806.xml","form_type":"4"}},{"id":3016205,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2020-10-02T20:32:56.000Z","date":"2020-09-30","kind":"tax_withholding","acquired":false,"shares":5446,"price":25.14,"value":136912.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by and surrendered to the Issuer on September 30, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of the PSA."}],"balance_after":49862,"source":{"system":"sec-edgar","filing":"0001628280-20-014242","document":"wf-form4_160168515859266.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000162828020014242/wf-form4_160168515859266.xml","form_type":"4"}},{"id":3016204,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2020-10-02T20:32:56.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":15750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock received upon partial settlement of a performance share award (the \"PSA\") on September 30, 2020."}],"balance_after":55308,"source":{"system":"sec-edgar","filing":"0001628280-20-014242","document":"wf-form4_160168515859266.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000162828020014242/wf-form4_160168515859266.xml","form_type":"4"}},{"id":3091768,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2020-07-02T20:18:10.000Z","date":"2020-06-30","kind":"other","acquired":true,"shares":763,"price":13.7955,"value":10525.9665,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2020 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":39558,"source":{"system":"sec-edgar","filing":"0001479290-20-000076","document":"wf-form4_159373545085161.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929020000076/wf-form4_159373545085161.xml","form_type":"4"}},{"id":3263141,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2020-02-19T20:21:25.000Z","date":"2020-02-15","kind":"tax_withholding","acquired":false,"shares":576,"price":25.33,"value":14590.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock Award (\"RSA\") for 1,666 shares.  The RSA vests in three equal annual installments from February 15, 2019, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) on each vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The fair market value was determined on February 14, 2020 pursuant to the Plan."}],"balance_after":38795,"source":{"system":"sec-edgar","filing":"0001479290-20-000031","document":"wf-form4_158216166821994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929020000031/wf-form4_158216166821994.xml","form_type":"4"}},{"id":3302953,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-01-24T20:21:16.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":97500,"price":22.32,"value":2176200.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from January 23, 2020, subject to Mr. Schilke's Continuous Service (as defined in the Plan) on each vesting date."}],"balance_after":97500,"derivative":{"exercise_price":22.32,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":97500},"source":{"system":"sec-edgar","filing":"0001479290-20-000019","document":"wf-form4_157991525885149.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929020000019/wf-form4_157991525885149.xml","form_type":"4"}},{"id":3302952,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2020-01-24T20:21:16.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the Restricted Stock Award shall vest in three (3) equal annual installments beginning from February 15, 2020, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan(the \"Plan\")) on each vesting date."}],"balance_after":39371,"source":{"system":"sec-edgar","filing":"0001479290-20-000019","document":"wf-form4_157991525885149.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929020000019/wf-form4_157991525885149.xml","form_type":"4"}},{"id":3322945,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2020-01-03T18:42:02.000Z","date":"2019-12-31","kind":"other","acquired":true,"shares":504,"price":10.82,"value":5453.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan (the \"Plan\") on December 31, 2019 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).  Mr. Schilke purchased the maximum number of shares allowable under the Issuer's Plan and Internal Revenue Code Section 423(b)(8) for the period ended December 31, 2019."}],"balance_after":22871,"source":{"system":"sec-edgar","filing":"0001479290-20-000002","document":"wf-form4_157809490379524.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929020000002/wf-form4_157809490379524.xml","form_type":"4"}},{"id":3338915,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2019-12-17T19:57:56.000Z","date":"2019-12-15","kind":"tax_withholding","acquired":false,"shares":1556,"price":15.99,"value":24880.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award (\"RSA\") for 4,500 shares.  The RSA vests in four equal annual installments from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date."}],"balance_after":22367,"source":{"system":"sec-edgar","filing":"0001479290-19-000115","document":"wf-form4_157663065876390.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929019000115/wf-form4_157663065876390.xml","form_type":"4"}},{"id":3471206,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2019-07-02T21:16:41.000Z","date":"2019-06-28","kind":"other","acquired":true,"shares":923,"price":11.0245,"value":10175.6135,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 28, 2019 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":23923,"source":{"system":"sec-edgar","filing":"0001479290-19-000077","document":"wf-form4_156211658648634.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929019000077/wf-form4_156211658648634.xml","form_type":"4"}},{"id":3686729,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-01-25T21:00:49.000Z","date":"2019-01-24","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from January 24, 2019, subject to Mr. Schilke's Continuous Service (as defined in the Plan) on each vesting date."}],"balance_after":30000,"derivative":{"exercise_price":17.23,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001479290-19-000017","document":"wf-form4_154846803275133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929019000017/wf-form4_154846803275133.xml","form_type":"4"}},{"id":3686728,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2019-01-25T21:00:49.000Z","date":"2019-01-24","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from February 15, 2019, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) on each vesting date."}],"balance_after":23000,"source":{"system":"sec-edgar","filing":"0001479290-19-000017","document":"wf-form4_154846803275133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929019000017/wf-form4_154846803275133.xml","form_type":"4"}},{"id":3771514,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-11-07T20:31:38.000Z","date":"2018-11-05","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest over a period of four years commencing on November 5, 2018, with 25% vesting on the annual anniversary of the vesting commencement date and 1/48th vesting each month thereafter over the remaining three years, subject to Mr. Schilke's Continuous Service (as defined in the Plan) through each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":24.96,"expiration_date":"2028-11-04","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001479290-18-000112","document":"wf-form4_154164068216658.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000112/wf-form4_154164068216658.xml","form_type":"4"}},{"id":3771513,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2018-11-07T20:31:38.000Z","date":"2018-11-05","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the Restricted Stock award shall vest in four (4) equal annual installments beginning from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan(the \"Plan\")) on each vesting date."}],"balance_after":18000,"source":{"system":"sec-edgar","filing":"0001479290-18-000112","document":"wf-form4_154164068216658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000112/wf-form4_154164068216658.xml","form_type":"4"}},{"id":3881289,"issuer":{"id":158957,"kind":"organization","name":"Achaogen, Inc.","symbol":"AKAO"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-28T16:20:41.000Z","date":"2018-06-26","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 8, 2018, the issuer granted the reporting person Restricted Stock Units (\"RSUs\") and a stock option that each vest upon the achievement of certain milestones. On June 26, 2018, one of the milestones was achieved, resulting in vesting of a portion of the RSUs and shares subject to the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested and exercisable."}],"balance_after":4000,"derivative":{"exercise_price":10.64,"expiration_date":"2028-02-08","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001140361-18-030425","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1301501/000114036118030425/doc1.xml","form_type":"4"}},{"id":3881288,"issuer":{"id":158957,"kind":"organization","name":"Achaogen, Inc.","symbol":"AKAO"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-28T16:20:41.000Z","date":"2018-06-26","kind":"sale","acquired":false,"shares":298,"price":9.59,"value":2857.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of RSUs of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 31,730 RSUs."}],"balance_after":47748,"source":{"system":"sec-edgar","filing":"0001140361-18-030425","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1301501/000114036118030425/doc1.xml","form_type":"4"}},{"id":3881287,"issuer":{"id":158957,"kind":"organization","name":"Achaogen, Inc.","symbol":"AKAO"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-28T16:20:41.000Z","date":"2018-06-26","kind":"grant","acquired":true,"shares":860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 8, 2018, the issuer granted the reporting person Restricted Stock Units (\"RSUs\") and a stock option that each vest upon the achievement of certain milestones. On June 26, 2018, one of the milestones was achieved, resulting in vesting of a portion of the RSUs and shares subject to the option."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 31,730 RSUs."}],"balance_after":48046,"source":{"system":"sec-edgar","filing":"0001140361-18-030425","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1301501/000114036118030425/doc1.xml","form_type":"4"}},{"id":3895270,"issuer":{"id":158957,"kind":"organization","name":"Achaogen, Inc.","symbol":"AKAO"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-13T17:03:33.000Z","date":"2018-06-11","kind":"sale","acquired":false,"shares":2087,"price":11.95,"value":24939.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\") of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 31,730 RSUs and (ii) 2,208 shares acquired under the issuer's Employee Stock Purchase Plan on May 31, 2018."}],"balance_after":47186,"source":{"system":"sec-edgar","filing":"0001140361-18-028440","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1301501/000114036118028440/doc1.xml","form_type":"4"}},{"id":3932707,"issuer":{"id":158957,"kind":"organization","name":"Achaogen, Inc.","symbol":"AKAO"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T18:33:17.000Z","date":"2018-02-08","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of February 8, 2018, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":32000,"derivative":{"exercise_price":10.64,"expiration_date":"2028-02-08","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001140361-18-024054","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1301501/000114036118024054/doc1.xml","form_type":"4"}},{"id":3932706,"issuer":{"id":158957,"kind":"organization","name":"Achaogen, Inc.","symbol":"AKAO"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-05-15T18:33:17.000Z","date":"2018-02-08","kind":"grant","acquired":true,"shares":6880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSUs\"). The reporting person is entitled to one (1) share of Common Stock for each one (1) RSU upon the vesting thereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 37,105 Restricted Stock Units."}],"balance_after":47065,"source":{"system":"sec-edgar","filing":"0001140361-18-024054","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1301501/000114036118024054/doc1.xml","form_type":"4"}},{"id":4036756,"issuer":{"id":158957,"kind":"organization","name":"Achaogen, Inc.","symbol":"AKAO"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-23T20:38:04.000Z","date":"2018-02-21","kind":"sale","acquired":false,"shares":1108,"price":10.67,"value":11822.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\") of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 1,174 shares acquired under the issuer's Employee Stock Purchase Plan on November 30, 2017 and (ii) 30,225 Restricted Stock Units."}],"balance_after":40185,"source":{"system":"sec-edgar","filing":"0001140361-18-009970","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1301501/000114036118009970/doc1.xml","form_type":"4"}},{"id":4282104,"issuer":{"id":158957,"kind":"organization","name":"Achaogen, Inc.","symbol":"AKAO"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-06-14T19:39:02.000Z","date":"2017-06-12","kind":"sale","acquired":false,"shares":2066,"price":21.53,"value":44480.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\") of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 32,925 RSUs and (ii) 2,640 shares acquired under the issuer's Employee Stock Purchase Plan on May 31, 2017."}],"balance_after":40119,"source":{"system":"sec-edgar","filing":"0001140361-17-025045","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1301501/000114036117025045/doc1.xml","form_type":"4"}},{"id":4424358,"issuer":{"id":158957,"kind":"organization","name":"Achaogen, Inc.","symbol":"AKAO"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-24T20:13:58.000Z","date":"2017-02-22","kind":"grant","acquired":true,"shares":12600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option shall vest on the following schedule: (i) 40% of the shares subject to the option will vest on the 30th consecutive date that the closing trading price of the Issuer's common stock first reaches or exceeds $30.00 per share; (ii) 40% of the shares subject to the option will vest on the 30th consecutive date that the closing trading price of the Issuer's common stock first reaches or exceeds $40.00 per share; and (iii) 20% of the shares subject to the option will vest on the 30th consecutive date that the closing trading price of the Issuer's common stock first reaches or exceeds $55.00 per share, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date and as appropriately adjusted for stock splits, stock dividends, recapitalizations and the like."}],"balance_after":12600,"derivative":{"exercise_price":23.62,"expiration_date":"2026-02-22","underlying":"Common Stock","underlying_shares":12600},"source":{"system":"sec-edgar","filing":"0001140361-17-009245","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1301501/000114036117009245/doc1.xml","form_type":"4"}},{"id":4424357,"issuer":{"id":158957,"kind":"organization","name":"Achaogen, Inc.","symbol":"AKAO"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-24T20:13:58.000Z","date":"2017-02-22","kind":"grant","acquired":true,"shares":50400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of February 22, 2017, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":50400,"derivative":{"exercise_price":23.62,"expiration_date":"2026-02-22","underlying":"Common Stock","underlying_shares":50400},"source":{"system":"sec-edgar","filing":"0001140361-17-009245","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1301501/000114036117009245/doc1.xml","form_type":"4"}},{"id":4424356,"issuer":{"id":158957,"kind":"organization","name":"Achaogen, Inc.","symbol":"AKAO"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-02-24T20:13:58.000Z","date":"2017-02-22","kind":"grant","acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSUs\"). The reporting person is entitled to one (1) share of Common Stock for each one (1) RSU upon the vesting thereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 38,300 RSUs."}],"balance_after":39545,"source":{"system":"sec-edgar","filing":"0001140361-17-009245","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1301501/000114036117009245/doc1.xml","form_type":"4"}},{"id":4477128,"issuer":{"id":158957,"kind":"organization","name":"Achaogen, Inc.","symbol":"AKAO"},"owners":[{"id":17929,"kind":"person","name":"Schilke Tobin","position":1,"cik":"0001678984","reported_name":"Schilke Tobin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-01-30T21:38:25.000Z","date":"2017-01-26","kind":"sale","acquired":false,"shares":955,"price":16.78,"value":16024.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 24,800 Restricted Stock Units."}],"balance_after":26045,"source":{"system":"sec-edgar","filing":"0001140361-17-003552","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1301501/000114036117003552/doc1.xml","form_type":"4"}}]}